Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study

Jennifer C. E. Lane, James Weaver, Kristin Kostka, Talita Duarte‐Salles, Maria Tereza Fernandes Abrahão, Heba Alghoul, Osaid Alser, Thamir M. Alshammari, Patricia Biedermann, Edward Burn, Paula Casajust, Mitch Conover, Aedín C. Culhane, Alexander Davydov, Scott L. DuVall, Dmitry Dymshyts, Sergio Fernández‐Bertolín, Kristina Fišter, Jill Hardin, Laura Hester, George Hripcsak, Seamus Kent, Sajan Khosla, Spyros Kolovos, Christophe G Lambert, Johan van der Lei, Ajit Londhe, Kristine E. Lynch, Rupa Makadia, Andrea V. Margulis, Michael E. Matheny, Paras Mehta, Daniel R. Morales, Henry Morgan-Stewart, Mees Mosseveld, Danielle Newby, Fredrik Nyberg, Anna Ostropolets, Rae Woong Park, Albert Prats‐Uribe, Gowtham Rao, Christian Reich, Jenna Reps, Peter R. Rijnbeek, Selva Muthu Kumaran Sathappan, Martijn J. Schuemie, Sarah Seager, Anthony G. Sena, Azza Shoaibi, Henry M. Spotnitz, Marc A. Suchard, Joel N. Swerdel, Carmen Olga Torre, David Vizcaya, Haini Wen, Marcel de Wilde, Seng Chan You, Lin Zhang, Oleg Zhuk, Patrick Ryan, Daniel Prieto‐AlhambramedRxiv 2020 · DOI

Abstract

Early in the COVID-19 pandemic, hydroxychloroquine (HCQ) was widely prescribed, often alongside azithromycin (AZM), despite limited safety data. This study evaluated the safety of HCQ alone and in combination with AZM across 14 databases in six countries. Using a new-user cohort design and self-controlled case series, researchers compared HCQ to sulfasalazine, and HCQ+AZM to HCQ+amoxicillin. While short-term HCQ use (30 days) showed no increased risk of severe adverse events (SAEs), the combination of HCQ and AZM was associated with a significant increase in cardiovascular mortality (CalHR 2.19), heart failure, and chest pain. These findings suggest that while HCQ monotherapy is relatively safe for short-term use, its combination with azithromycin poses substantial cardiac risks.

Introduction

The rapid, global adoption of hydroxychloroquine—often paired with the antibiotic azithromycin—as a potential treatment for COVID-19 created an urgent need for robust safety evidence. Initial enthusiasm was driven by small-scale observational studies, but concerns regarding cardiotoxicity, specifically QT prolongation and lethal arrhythmias, remained unaddressed at scale. This study sought to provide a definitive assessment of the real-world safety of these treatments using a massive, multinational patient population.

Methods and Data Sources

This research was conducted through the Observational Health Data Sciences and Informatics (OHDSI) consortium, utilizing a distributed network approach. Standardized analysis code was deployed across 14 databases in Germany, Japan, the Netherlands, Spain, the UK, and the USA, encompassing electronic health records and administrative claims.

Study Population

The study included over 956,374 HCQ users and 310,350 sulfasalazine users for the primary safety comparison. To isolate the effect of the antibiotic combination, the researchers also analyzed 323,122 users of HCQ+AZM and 351,956 users of HCQ+amoxicillin.

Analytical Framework

Two primary designs were employed to ensure robustness:

  1. New User Cohort Study: Comparing patients initiating HCQ against those starting sulfasalazine (an active comparator for rheumatoid arthritis) to minimize selection bias.
  2. Self-Controlled Case Series (SCCS): Using patients as their own controls to eliminate time-invariant confounding factors like genetics.

To address residual confounding, the team used large-scale propensity score (PS) stratification—incorporating tens of thousands of covariates—and empirical calibration using negative control outcomes to detect and correct for systematic bias.

Key Insights

The Safety of Monotherapy

Short-term (30-day) use of hydroxychloroquine alone did not show an increased risk for any of the 16 severe adverse events studied when compared to sulfasalazine. This suggests that for typical indications, such as the initial treatment of rheumatoid arthritis, HCQ maintains a favorable safety profile.

The Lethal Synergy of Combination Therapy

A critical safety signal emerged when azithromycin was added to hydroxychloroquine. Compared to the combination of HCQ and amoxicillin, the HCQ+AZM regimen was associated with:

  • Cardiovascular Mortality: A 2.19-fold increased risk (CalHR 2.19 [1.22-3.94]).
  • Heart Failure: A 22% increased risk (CalHR 1.22 [1.02-1.45]).
  • Chest Pain/Angina: A 15% increased risk (CalHR 1.15 [1.05-1.26]).

Cumulative vs. Acute Risk

While short-term use appeared safe, long-term chronic use of HCQ was associated with a 65% increase in cardiovascular mortality (CalHR 1.65). This suggests that the cardiac risks of HCQ may be cumulative over time, necessitating careful monitoring for patients on long-term therapy.

Undetected Cardiac Events

Interestingly, while cardiovascular mortality increased, there was no corresponding increase in diagnosed arrhythmias. This suggests that the deaths may have been sudden and undetected, potentially caused by torsade de pointes or other arrhythmias triggered by the synergistic effect of both drugs on the heart's QT interval.

Discussion and Limitations

The study's methodological rigor—using active comparators and negative controls—provides a high level of confidence in these safety signals. However, some limitations remain. The study population was primarily composed of patients with rheumatoid arthritis; while they serve as a reliable proxy for drug safety, their baseline risk may differ from patients with acute COVID-19. Furthermore, the doses used in chronic conditions are often lower than the high loading doses initially proposed for COVID-19 treatment, meaning the risks in a pandemic context could be even higher than reported here.

Conclusion

Short-term hydroxychloroquine treatment is generally safe, but the addition of azithromycin significantly increases the risk of heart failure and cardiovascular mortality. These results serve as a strong warning against the unmonitored use of the HCQ+AZM combination. Clinicians should exercise extreme caution and prioritize cardiac monitoring if this combination is considered, particularly in patients with pre-existing cardiovascular vulnerabilities.

Summary updated

Abstract

ABSTRACT Background Hydroxychloroquine has recently received Emergency Use Authorization by the FDA and is currently prescribed in combination with azithromycin for COVID-19 pneumonia. We studied the safety of hydroxychloroquine, alone and in combination with azithromycin. Methods New user cohort studies were conducted including 16 severe adverse events (SAEs). Rheumatoid arthritis patients aged 18+ and initiating hydroxychloroquine were compared to those initiating sulfasalazine and followed up over 30 days. Self-controlled case series (SCCS) were conducted to further establish safety in wider populations. Separately, SAEs associated with hydroxychloroquine- azithromycin (compared to hydroxychloroquine-amoxicillin) were studied. Data comprised 14 sources of claims data or electronic medical records from Germany, Japan, Netherlands, Spain, UK, and USA. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate calibrated hazard ratios (CalHRs) according to drug use. Estimates were pooled where I2<40%. Results Overall, 956,374 and 310,350 users of hydroxychloroquine and sulfasalazine, and 323,122 and 351,956 users of hydroxychloroquine-azithromycin and hydroxychloroquine-amoxicillin were included. No excess risk of SAEs was identified when 30-day hydroxychloroquine and sulfasalazine use were compared. SCCS confirmed these findings. However, when azithromycin was added to hydroxychloroquine, we observed an increased risk of 30-day cardiovascular mortality (CalHR2.19 [1.22- 3.94]), chest pain/angina (CalHR 1.15 [95% CI 1.05-1.26]), and heart failure (CalHR 1.22 [95% CI 1.02- 1.45]) Conclusions Short-term hydroxychloroquine treatment is safe, but addition of azithromycin may induce heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length. We call for caution if such combination is to be used in the management of Covid-19. Trial registration number Registered with EU PAS; Reference number EUPAS34497 ( http://www.encepp.eu/encepp/viewResource.htm?id=34498 ). The full study protocol and analysis source code can be found at https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine . Funding sources This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and Senior Research Fellowship (DPA), US National Institutes of Health, Janssen Research & Development, IQVIA, and by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992]. Personal funding included Versus Arthritis [21605] (JL), MRC-DTP [MR/K501256/1] (JL), MRC and FAME (APU). The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, NHS or the Department of Health, England.
BibTeX
@misc{lane2020safety,
  author = {Jennifer C. E. Lane and James Weaver and Kristin Kostka and Talita Duarte‐Salles and Maria Tereza Fernandes Abrahão and Heba Alghoul and Osaid Alser and Thamir M. Alshammari and Patricia Biedermann and Edward Burn and Paula Casajust and Mitch Conover and Aedín C. Culhane and Alexander Davydov and Scott L. DuVall and Dmitry Dymshyts and Sergio Fernández‐Bertolín and Kristina Fišter and Jill Hardin and Laura Hester and George Hripcsak and Seamus Kent and Sajan Khosla and Spyros Kolovos and Christophe G Lambert and Johan van der Lei and Ajit Londhe and Kristine E. Lynch and Rupa Makadia and Andrea V. Margulis and Michael E. Matheny and Paras Mehta and Daniel R. Morales and Henry Morgan-Stewart and Mees Mosseveld and Danielle Newby and Fredrik Nyberg and Anna Ostropolets and Rae Woong Park and Albert Prats‐Uribe and Gowtham Rao and Christian Reich and Jenna Reps and Peter R. Rijnbeek and Selva Muthu Kumaran Sathappan and Martijn J. Schuemie and Sarah Seager and Anthony G. Sena and Azza Shoaibi and Henry M. Spotnitz and Marc A. Suchard and Joel N. Swerdel and Carmen Olga Torre and David Vizcaya and Haini Wen and Marcel de Wilde and Seng Chan You and Lin Zhang and Oleg Zhuk and Patrick Ryan and Daniel Prieto‐Alhambra},
  title = {{Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study}},
  year = {2020},
  doi = {10.1101/2020.04.08.20054551},
  howpublished = {medRxiv},
}
Figure